This agrees perfectly with what we found in the literature, where strong evidence shows that IDH1 mutation is associated with a better prognosis for GBM patients [54,55,56], and on the other hand, EGFR mutation with a worse one [57]. The gene discussed is EGFR; the disease is glioblastoma.